Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.

Abstract:

:We performed a randomized, controlled clinical trial to characterize the evolution of the adverse events associated with the fifth consecutive dose of an acellular pertussis vaccine, and to assess the level of discomfort associated with the injection and the attitude of parents concerning these events. A total of 505 children who had received either four doses of acellular pertussis vaccine or whole-cell pertussis vaccine were given a fifth dose of one of the two vaccines. Adverse events were monitored by parents and collected by telephone or home visit at 4, 8, 12, 24, 48 and 72 h, and 7 and 28 days after immunization. Rates of injection site redness >or=50mm were similar in recipients of five doses of acellular pertussis vaccine (32.8%) or five doses of whole-cell pertussis vaccine (43.3%). Injection site swelling, tenderness, and decreased arm movement were all more frequent in children who received five doses of whole-cell pertussis vaccine. Antibody levels before or after immunization did not predict those children who had increased injection site reactions. The children rated the injection site reactions as significantly more severe after five consecutive doses of whole-cell vaccine. Parent satisfaction was higher after the acellular vaccine. We conclude that a fifth consecutive dose of a whole-cell pertussis vaccine is associated with high rates of tender redness and swelling at the injection site, in contrast to a fifth consecutive dose of an acellular pertussis vaccine which is associated with high rates of non-painful redness. However, parents will still need to be aware of the high rates of injection site reactions expected after a fifth dose of acellular pertussis vaccine.

journal_name

Vaccine

journal_title

Vaccine

authors

Halperin SA,Scheifele D,Mills E,Guasparini R,Humphreys G,Barreto L,Smith B

doi

10.1016/s0264-410x(03)00173-7

subject

Has Abstract

pub_date

2003-06-02 00:00:00

pages

2298-306

issue

19-20

eissn

0264-410X

issn

1873-2518

pii

S0264410X03001737

journal_volume

21

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

相关文献

VACCINE文献大全
  • Influenza vaccination in a healthy geriatric population: preferential induction of antibodies specific for the H3N2 influenza strain despite equal T cell responsiveness to all vaccine strains.

    abstract::Cellular as well as humoral immune reactivity were studied in healthy young (< 30 years; n = 12) and older (> 65 years; n = 12) individuals before as well as 1 month after immunization with a trivalent whole virus influenza vaccine. Before vaccination, peripheral blood mononuclear cell proliferation in response to in ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)88329-6

    authors: Saurwein-Teissl M,Steger MM,Glück R,Cryz S,Grubeck-Loebenstein B

    更新日期:1998-01-01 00:00:00

  • Assessing vaccine potency using TCRmimic antibodies.

    abstract::Dendritic cells (DCs) are highly specialized antigen-presenting cells of the immune system that are efficient at presenting peptide-antigen for the activation of T cells and are often the cell type of choice for vaccine targeting by virtue of high expression levels of MHC and costimulatory molecules. Since the level o...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.02.025

    authors: Neethling FA,Ramakrishna V,Keler T,Buchli R,Woodburn T,Weidanz JA

    更新日期:2008-06-13 00:00:00

  • Immunological solutions for treatment and prevention of porcine reproductive and respiratory syndrome (PRRS).

    abstract::Vaccination is the principal means used to control and treat porcine reproductive and respiratory syndrome virus (PRRSV) infection. An array of PRRS vaccine products is available in various regions of the world. However, despite extensive efforts, little progress has been made to improve efficacy since the first intro...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2011.09.013

    authors: Murtaugh MP,Genzow M

    更新日期:2011-10-26 00:00:00

  • Is the pneumococcal vaccine Advance Market Commitment motivating innovation and increasing manufacturing capacity? Some preliminary answers.

    abstract::This paper seeks to give some preliminary evidence on the potential outcome of the pneumococcal vaccine Advance Market Commitment (AMC), with a focus on its impact on innovation in 'emerging' vaccine manufacturers in developing countries. The evidence is derived from a series of interviews with executives at industria...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.01.046

    authors: Plahte J

    更新日期:2012-03-23 00:00:00

  • Delivery of antigen to sialoadhesin or CD163 improves the specific immune response in pigs.

    abstract::Delivery of antigens to antigen presenting cell surface receptors represents a promising strategy to improve immune response to weak immunogenic antigens. We have analyzed the potential of porcine sialoadhesin (Sn) and CD163 as antigen targeting receptors using mouse Igs as surrogate antigens. Sn and CD163 are two end...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.04.076

    authors: Poderoso T,Martínez P,Álvarez B,Handler A,Moreno S,Alonso F,Ezquerra Á,Domínguez J,Revilla C

    更新日期:2011-06-24 00:00:00

  • HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.

    abstract::The Indian rhesus macaque is the established animal model for HIV infection and vaccine research. Growing evidence suggests that the more readily available Chinese rhesus macaque may be a more relevant option. As increasing numbers of novel Chinese rhesus MHC alleles are reported, we decided to explore potential HIV v...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.117

    authors: Liao Q,Strong AJ,Liu Y,Liu Y,Meng P,Fu Y,Touzjian N,Shao Y,Zhao Z,Lu Y

    更新日期:2012-02-21 00:00:00

  • Recombinant flagellins with deletions in domains D1, D2, and D3: Characterization as novel immunoadjuvants.

    abstract::Bacterial flagellin activates the innate immune system and ultimately the adaptive immune system through a Toll-like receptor 5 (TLR5)-dependent signaling mechanism. Given that TLR5 is widely distributed in epithelia, flagellin is currently being developed as a mucosal adjuvant. Flagellin FliC from Salmonella enterica...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.12.009

    authors: Biedma ME,Cayet D,Tabareau J,Rossi AH,Ivičak-Kocjan K,Moreno G,Errea A,Soulard D,Parisi G,Jerala R,Berguer P,Rumbo M,Sirard JC

    更新日期:2019-01-21 00:00:00

  • Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity.

    abstract::Rhesus-human rotavirus reassortants incorporating the gene expressing the VP7 surface protein of human rotavirus serotypes 1 or 2, and the remaining ten genes from rhesus rotavirus (RRV) were evaluated as candidate oral vaccines in 2-4-month-old infants. A single dose of the serotype 1 reassortant vaccine which had a ...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/0264-410x(91)90060-j

    authors: Vesikari T,Varis T,Green K,Flores J,Kapikian AZ

    更新日期:1991-05-01 00:00:00

  • Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis.

    abstract::We hypothesized that the ability of BCG vaccination to protect against Mycobacterium tuberculosis is less in hosts exposed to chronic helminthes infection compared to unexposed individuals. To test this hypothesis we evaluated the efficacy of BCG vaccination in protecting against M. tuberculosis challenge in Schistoso...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.09.038

    authors: Elias D,Akuffo H,Pawlowski A,Haile M,Schön T,Britton S

    更新日期:2005-02-03 00:00:00

  • Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity.

    abstract:OBJECTIVE:This study sought to evaluate the acceptability of inactivated influenza vaccine delivered by microneedle patch (MNP) in comparison to inactivated influenza vaccine (IIV) delivered by hypodermic needle. DESIGN, SETTING, AND PARTICIPANTS:From the general population of Atlanta, Georgia, we screened 112 and enr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.07.064

    authors: Frew PM,Paine MB,Rouphael N,Schamel J,Chung Y,Mulligan MJ,Prausnitz MR

    更新日期:2020-10-21 00:00:00

  • Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach.

    abstract::Currently, infections of hand, foot and mouth disease (HFMD) due to Human Enterovirus 71 (EV71) cannot be prevented or treated, as there are no suitable vaccines or antiviral drugs. This study aimed to identify potential vaccine candidates for EV71 using in silico analysis of its viral capsid proteins. A combined in s...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.09.030

    authors: Kirk K,Poh CL,Fecondo J,Pourianfar H,Shaw J,Grollo L

    更新日期:2012-11-19 00:00:00

  • The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection.

    abstract::The immunological properties of the Trypanosoma cruzi paraflagellar rod proteins (PFR2 and PFR3) administered alone as well as fused to HSP70 have been analyzed in mice in the context of genetic immunization. The immunization of mice with the DNA vectors containing the PFRs gene or PFRs-HSP70 fused genes induced high ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.07.006

    authors: Morell M,Thomas MC,Caballero T,Alonso C,López MC

    更新日期:2006-11-30 00:00:00

  • A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.

    abstract:BACKGROUND:To contribute to the global demand for oral cholera vaccine (OCV), the production of Euvichol® was scaled up with elimination of thimerosal. To demonstrate the equivalence of the variations, a study was carried out in the Philippines. METHODS:Healthy male and female adults and children in Manila were random...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2018.05.102

    authors: Russo P,Ligsay AD,Olveda R,Choi SK,Kim DR,Park JY,Park JY,Syed KA,Dey A,Kim YH,Lee SH,Kim J,Chon Y,Digilio L,Kim CW,Excler JL

    更新日期:2018-07-05 00:00:00

  • Lethal toxicity and adjuvant activities of synthetic TDM and its related compounds in mice.

    abstract::Trehalose-6,6'-dimycolate (TDM) and its monosaccharide-type analogues were synthesized, and their lethal and adjuvant activities were examined in mice. All the monosaccharide-type analogues with a glucose or N-acetylglucosamine moiety were devoid of lethal toxicity to mice; in particular, D-GlcNAcM(1-deoxy) and D-GlcN...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(89)90242-9

    authors: Sakurai T,Saiki I,Ishida H,Takeda K,Azuma I

    更新日期:1989-06-01 00:00:00

  • Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.

    abstract::FHbp is a major serogroup B meningococcal vaccine antigen. Binding of complement Factor H (FH) to FHbp is specific for human and some non-human primate FH. In previous studies, FH binding to FHbp vaccines impaired protective anti-FHbp antibody responses. In this study we investigated anti-FHbp antibody responses to a ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.10.135

    authors: Giuntini S,Beernink PT,Granoff DM

    更新日期:2015-12-16 00:00:00

  • Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.

    abstract::In order to evaluate the immunogenicity, safety, and tolerability of the MF-59 adjuvanted seasonal influenza vaccine in children and adolescents with juvenile idiopathic arthritis (JIA) treated with different anti-rheumatic drugs, 60 pediatric patients with JIA (30 treated with disease-modifying anti-rheumatic drugs [...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.11.083

    authors: Dell'Era L,Corona F,Daleno C,Scala A,Principi N,Esposito S

    更新日期:2012-01-20 00:00:00

  • Impact of unfounded vaccine safety concerns on the nationwide measles-rubella immunization campaign, Georgia, 2008.

    abstract::Vaccine safety fears following media reports of adverse events led to low (50.3%) coverage in a supplementary measles-rubella immunization campaign in Georgia in 2008. Review of adverse events associated with the campaign identified 432 reports (<0.1% of ∼ 493,000 vaccinees) including 338 (78.2%) cases of syncope. The...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.07.043

    authors: Khetsuriani N,Imnadze P,Baidoshvili L,Jabidze L,Tatishili N,Kurtsikashvili G,Lezhava T,Laurent E,Martin R

    更新日期:2010-09-07 00:00:00

  • The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice.

    abstract::We have previously described the generation of HIV-1 V3-specific cytotoxic T-lymphocytes (CTL) responses in BALB/c (H-2d) mice following immunization with Ty-virus-like particles carrying the V3 loop of gp120 (V3-VLPs) without adjuvant. In this study the effects of various adjuvants on CTL induction by V3-VLPs was exa...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(96)00010-2

    authors: Harris SJ,Woodrow SA,Gearing AJ,Adams SE,Kingsman AJ,Layton GT

    更新日期:1996-07-01 00:00:00

  • Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia, Spain.

    abstract::The prevalence of seropositive individuals that makes costs of vaccinating all individuals equal to that for screening and vaccination of susceptible individuals is defined as the critical prevalence of antibodies (p*). Screening and vaccination is more efficient when the prevalence of seropositive individuals (p) in ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.03.048

    authors: Plans-Rubió P

    更新日期:2004-09-28 00:00:00

  • Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies.

    abstract::Serogroup X Neisseria meningitidis (MenX) has recently emerged as a cause of localized disease outbreaks in sub-Saharan Africa. In order to prepare for vaccine development, MenX polysaccharide (MenX PS) was purified by standard methods and analyzed for identity and structure by NMR spectroscopy. This study presents th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.07.032

    authors: Xie O,Bolgiano B,Gao F,Lockyer K,Swann C,Jones C,Delrieu I,Njanpop-Lafourcade BM,Tamekloe TA,Pollard AJ,Norheim G

    更新日期:2012-08-31 00:00:00

  • Antigenic differentiation of classical swine fever vaccinal strain PAV-250 from other strains, including field strains from Mexico.

    abstract::Twenty-nine classical swine fever virus (CSFv) strains were grown in the PK15 or SK6 cell lines. Antigenic differentiation studies were performed using monoclonal antibodies (McAbs), produced at Lelystad (CDI-DLO), The Netherlands. The monoclonals which were classified numerically as monoclonals 2-13. Epitope map patt...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.07.045

    authors: Mendoza S,Correa-Giron P,Aguilera E,Colmenares G,Torres O,Cruz T,Romero A,Hernandez-Baumgarten E,Ciprián A

    更新日期:2007-10-10 00:00:00

  • High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.

    abstract:PURPOSE:We conducted a cancer vaccine clinical trial with MAGE-A4 protein. Safety, clinical response, and antigen-specific immune responses were analyzed and the prognostic factors by vaccination were investigated. EXPERIMENTAL DESIGN:Twenty patients with advanced esophageal, stomach or lung cancer were administered M...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.09.002

    authors: Saito T,Wada H,Yamasaki M,Miyata H,Nishikawa H,Sato E,Kageyama S,Shiku H,Mori M,Doki Y

    更新日期:2014-10-14 00:00:00

  • Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens.

    abstract::With tuberculosis continuing to be a major cause of global morbidity and mortality, a new vaccine is urgently needed. Tuberculosis subunit vaccines have been shown to induce robust immune responses in humans and are a potentially safer alternative to BCG for use in HIV-endemic areas. In this study, we investigated the...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.07.032

    authors: Derrick SC,Yabe IM,Yang A,Kolibab K,Hollingsworth B,Kurtz SL,Morris S

    更新日期:2013-09-23 00:00:00

  • Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge.

    abstract::Strains of Newcastle disease virus (NDV) can be separated into genotypes based on genome differences even though they are antigenically considered to be of a single serotype. It is widely recognized that an efficacious Newcastle disease (ND) vaccine made with any NDV does induce protection against morbidity and mortal...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.07.017

    authors: Miller PJ,King DJ,Afonso CL,Suarez DL

    更新日期:2007-10-10 00:00:00

  • Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.

    abstract::Respiratory syncytial virus (RSV) is the primary cause of serious lower respiratory tract illness in young children. We have engineered a recombinant candidate vaccine G1F/M2, consisting of a cytotoxic T lymphocyte (CTL) epitope of RSV-M2 protein and a domain of RSV-G protein. In this study, the long-term immunogenici...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.08.007

    authors: Zeng R,Qi X,Gong W,Mei X,Wei L,Ma C,Yin X

    更新日期:2007-10-16 00:00:00

  • Measles vaccination of young infants in China: A cost-effectiveness analysis.

    abstract:BACKGROUND:Although global progress in measles control has been realized, achieving elimination has proven difficult in many regions of the world. China has adopted a goal of measles elimination but recent outbreaks predominantly affecting children <8 months who are ineligible for vaccination and incompletely protected...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.04.079

    authors: Janusz CB,Wagner AL,Masters NB,Ding Y,Zhang Y,Hutton DW,Boulton ML

    更新日期:2020-06-15 00:00:00

  • Meningitis epidemics in Africa: a brief overview.

    abstract::Every year, meningococcal meningitis causes thousands of deaths within the meningitis belt in sub-Saharan African countries. Large epidemic waves occur with a periodicity of 5-12 years. The waves do correspond to molecular changes in the expression of capsular or subcapsular antigens, which allow the bug to spread in ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2007.04.032

    authors: Teyssou R,Muros-Le Rouzic E

    更新日期:2007-09-03 00:00:00

  • Serological responses of rams to a Brucella ovis-vitamin E adjuvant vaccine.

    abstract::Rams which were vaccinated at 6-8 months of age with a water-in-oil Brucella ovis-vitamin E adjuvant vaccine had significantly higher serum antibody levels than rams vaccinated with a commercial B. ovis bacterin or B. melitensis Rev 1. The adjuvant vaccine did not cause abscesses at the site of injection as some water...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(91)90111-i

    authors: Tengerdy RP,Ameghino E,Riemann H

    更新日期:1991-04-01 00:00:00

  • Antigen adsorbed surface modified poly-ɛ-caprolactone microspheres stimulates both adaptive and innate immune response in fish.

    abstract::Surface modified poly-ɛ-caprolactone microspheres as an antigen carrier was explored in a fish model. Outer membrane vesicles of Edwardsiella tarda adsorbed on to surface modified poly-ɛ-caprolactone microspheres with chitosan and alginate induces both innate and adaptive immune responses which persist up to 63 days o...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.05.028

    authors: Behera T,Swain P

    更新日期:2012-07-27 00:00:00

  • Effect of hepatitis A vaccination schedules on immune response.

    abstract::An inactivated hepatitis A vaccine was given to 104 seronegative volunteers aged between 19 and 60 years according to two schedules: 0, 1 and 2 months or 0, 1 and 6 months. The vaccine was well tolerated and 97 and 100% of vaccinees developed a serum antibody response following a single and two doses of vaccine respec...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0264-410x(92)90563-y

    authors: Tilzey AJ,Palmer SJ,Barrow S,Perry KR,Tyrell H,Safary A,Banatvala JE

    更新日期:1992-01-01 00:00:00